Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 25Carcinoma, Non-Small-Cell Lung 14Squamous Cell Carcinoma of Head and Neck 11Melanoma 10Breast Neoplasms 10Urinary Bladder Neoplasms 9Colorectal Neoplasms 9Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Adenocarcinoma Of Esophagus 6Ovarian Neoplasms 5Liver Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Mesothelioma, Malignant 4Head and Neck Neoplasms 4Neoplasm Metastasis 3Mesothelioma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2

Interventions

tremelimumab 1durvalumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Immunoglobulin G 1Disulfides 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Malignant Female Reproductive System Neoplasm × tremelimumab × Clear all
NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡